Durvalumab Treatment Patterns for Patients with Unresectable Stage III Non-Small Cell Lung Cancer in the Veterans Health Administration (VHA): A Nationwide, Real-World Study

SIMPLE SUMMARY: Key Objective: Why do patients with unresectable stage III non-small cell lung cancer (NSCLC) experience durvalumab treatment initiation delays, interruptions, and discontinuations post-chemoradiotherapy (CRT)? Knowledge Generated: Toxicities are one of the main reasons for durvaluma...

Descripción completa

Detalles Bibliográficos
Autores principales: Moore, Amanda M., Nooruddin, Zohra, Reveles, Kelly R., Datta, Paromita, Whitehead, Jennifer M., Franklin, Kathleen, Alkadimi, Munaf, Williams, Madison H., Williams, Ryan A., Smith, Sarah, Reichelderfer, Renee, Cotarla, Ion, Brannman, Lance, Frankart, Andrew, Mulrooney, Tiernan, Hsieh, Kristin, Simmons, Daniel J., Jones, Xavier, Frei, Christopher R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10529719/
https://www.ncbi.nlm.nih.gov/pubmed/37754526
http://dx.doi.org/10.3390/curroncol30090611

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10529719/
https://www.ncbi.nlm.nih.gov/pubmed/37754526
http://dx.doi.org/10.3390/curroncol30090611

Ejemplares similares